Scalper1 News
An FDA advisory committee voted 13 to 3 late Tuesday in favor of approving cholesterol buster Praluent, though lingering questions remained about just how many people it will treat. Praluent, from the team-up of Regeneron Pharmaceuticals (REGN) and Sanofi (SNY), is due for a final decision on approval by July 31. Analysts expect multibillion-dollar annual sales eventually. While this would be significant even for big pharma Sanofi, it’s so crucial Scalper1 News
Scalper1 News